Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29971950 | 1.00 | DYRK1A (0.41) | DYRK1AMAPK1KDM4EALDH1A1MAPT | |
| SCHEMBL15612889 | 0.78 | DYRK1A (0.42) | DYRK1AMAPK1KDM4EALDH1A1MAPT | |
| SCHEMBL18558186 | 0.76 | CHEK1 (0.52) | DYRK1AMAPK1KDM4EALDH1A1MAPT | |
| SCHEMBL15612876 | 0.76 | KDM4E (0.42) | DYRK1AMAPK1KDM4EALDH1A1MAPT | |
| SCHEMBL30771351 | 0.76 | MTAP (0.43) | MAPK1LMNA | |
| SCHEMBL30677355 | 0.72 | MAPK1 (0.35) | MAPK1 | |
| SCHEMBL20524214 | 0.72 | MAPK1 (0.35) | MAPK1 | |
| SCHEMBL28380264 | 0.72 | MAPK1 (0.48) | DYRK1AMAPK1KDM4EALDH1A1MAPT | |
| SCHEMBL15613118 | 0.72 | DYRK1A (0.38) | DYRK1AMAPK1KDM4EALDH1A1MAPT | |
| SCHEMBL27409235 | 0.72 | DYRK1A (0.41) | DYRK1AMAPK1KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163226-A1 | NOVEL PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION INCLUDING SAME AS AN ACTIVE INGREDIENT | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2014-06-12 | — | — | US | claimed |
| EP-2738174-A2 | NOVEL PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION INCLUDING SAME AS AN ACTIVE INGREDIENT | Hanmi Pharmaceutical Co., Ltd. (KR) | 2014-06-04 | — | — | EP | claimed |
| US-20250346616-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2025-11-13 | — | — | US | disclosed |
| US-20250136606-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | US | disclosed |
| US-12234232-B2 | Aromatic heterocyclic compound with kinase inhibitory activity | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2025-02-25 | — | — | US | disclosed |
| US-20240398812-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| EP-4408849-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | Caraway Therapeutics, Inc. (US) | 2024-08-07 | — | — | EP | disclosed |
| EP-4408850-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | Caraway Therapeutics, Inc. (US) | 2024-08-07 | — | — | EP | disclosed |
| CN-118359621-A | Preparation method of intermediates of Li Siwei and Li Siwei and corresponding intermediates of Li Siwei | 上海陶术生物科技有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-118317963-A | TRPML modulators, compositions thereof, and methods of use | 卡拉韦治疗公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20230312556-A1 | ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| WO-2012093809-A2 | NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS | HANMI PHARM CO., LTD. (KR) | 2012-07-12 | — | — | WO | disclosed |
| WO-2011113798-A2 | NEW ENZYME INHIBITOR COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2011-09-22 | — | — | WO | disclosed |
| US-20100197678-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| US-20100197678-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| US-20100197678-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| CN-101547909-A | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM INT (DE) | 2009-09-30 | — | — | CN | disclosed |
| EP-2102170-A2 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008070507-A2 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008070507-A2 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346616-A1 | ROCK INHIBITORS AND USES THEREOF | ROCK1, ROCK2, RHOA | DYRK1A 2055/4885MAPK1 327/4885KDM4E 2213/4885 |
| US-20240398812-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | MCOLN1, PKD2, MCOLN3 | DYRK1A 4121/4885MAPK1 2467/4885KDM4E 4553/4885 |
| US-20100197678-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | NR3C1, NR3C2, MC2R | DYRK1A 1895/4885MAPK1 1449/4885KDM4E 2741/4885 |
| US-20140163226-A1 | NOVEL PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION INCLUDING SAME AS AN ACTIVE INGREDIENT | DGAT1, DGAT2, GART | DYRK1A 2275/4885MAPK1 1918/4885KDM4E 2498/4885 |
| US-20250136606-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | MCOLN1, TRPM2, PKD2 | DYRK1A 4084/4885MAPK1 2170/4885KDM4E 4568/4885 |
| US-12234232-B2 | Aromatic heterocyclic compound with kinase inhibitory activity | JAK1, JAK2, JAK3 | DYRK1A 886/4885MAPK1 64/4885KDM4E 452/4885 |
| US-20230312556-A1 | ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | AHR, ARNT, NOTUM | DYRK1A 3780/4885MAPK1 3042/4885KDM4E 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.